SIMCERE PHARMA plans to repurchase shares
SIMCERE PHARMA announced plans to repurchase up to 247 million shares, accounting for 10% of the issued shares. The board of directors decided to exercise the repurchase authorization on August 21, 2025, planning to repurchase in the open market for a total amount not exceeding 500 million RMB. The board stated that this move reflects confidence in the company's business prospects and will create value for shareholders, while the company has sufficient financial resources to maintain a sound financial condition
According to the announcement from SIMCERE PHARMA (02096), the company’s board of directors has been granted a general authorization to repurchase up to 247 million shares, accounting for 10% of the total issued shares as of June 13, 2025, based on the shareholder resolution passed at the annual general meeting held on that date.
On August 21, 2025, the board of directors resolved to exercise the repurchase authorization to repurchase shares in the open market for a total amount not exceeding RMB 500 million.
The board believes that repurchasing shares at this stage demonstrates the company's confidence in its business prospects and will ultimately benefit the company and create value for shareholders. Furthermore, the board believes that the financial resources currently available to the company are sufficient to conduct the proposed share repurchase while maintaining a sound financial position
